Patients with clinical Stage IB–IIA cancer of the uterine cervix treated by radical hysterectomy ,  bilateral pelvic lymphadenectomy ,  and aortic lymph node sampling were eligible for entry into this prospective study if they had one or more of the following risk factors ,  (1) metastatic disease to pelvic lymph nodes ,  (2) large primary tumors greater than or equal to 4 cm in diameter ,  (3) deeply invasive lesions with 75% or greater stromal invasion ,  (4) nonsquamous histology ,  and/or (5) occult parametrial involvement or positive surgical margins .
